Compare Amphastar Pharmaceuticals Inc (AMPH) vs Gold Fields Limited (GFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Gold Fields Limited — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.38 (market cap $826.08M), while Gold Fields Limited trades at $33.68 (market cap $30.43B). The key difference: Gold Fields Limited is far larger — about 36.8× Amphastar Pharmaceuticals Inc's market cap, and Gold Fields Limited pays a 6.79% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | GFI | |
|---|---|---|
Market Cap | $826.08M | $30.43B |
Sector | Health | Basic Materials |
52-Week High | $30.81 | $61.52 |
52-Week Low | $16.87 | $23.95 |
Enterprise Value | $1.22B | $31.87B |
Dividend Yield | — | 6.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Gold Fields (GFI) trades at $34.14, up 0.29% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company shows strong profitability with a 40.76% net income margin and 52.33% ROE, supported by revenue growth from $5.2B in 2024 to a projected $8.8B in 2025. Recent news highlights operational challenges amid gold price volatility, with Q1 2025 production up 15% but costs rising 13% due to inflation (Seeking Alpha, 2026-06-29).
The outlook is mixed: analyst consensus is a Buy with a $53.13 price target, implying 56% upside, but technical weakness and earnings misses in Q2 and Q4 2025 pose near-term risks. Long-term value hinges on cost control and gold price stability, with debt-to-asset ratio improvements from 25.01% in 2024 to 18.27% in 2025 signaling stronger balance sheet health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
